Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PDT, BFA

Armbrust American Debuts New Surgical Mask Colors as Demand Rises


AUSTIN, Texas, Aug. 4, 2020 /PRNewswire/ -- As wearing face coverings become the norm for society during the pandemic, Armbrust American is excited to announce that its FDA-registered surgical masks will now be available in six vibrant new colors. The masks have the same 98% effectiveness rating for blocking particulate matter, such as the novel coronavirus, while allowing the wearer a greater degree of self-expression like with cloth face coverings.

"People in the mask world thought I was crazy for making lab-tested surgical masks in cool colors instead of the usual 'medical blue' or aqua green, but it makes too much sense not to," said founder and CEO Lloyd Armbrust. "Now there's a safer, more effective option for people wearing cloth masks that match their favorite sports team or school colors, or businesses to replace workers' cloth face coverings with surgical masks matching the brand identity."

The new mask color options are available for pre-order immediately, with delivery dates in the next two weeks. Colors include "Creamsicle," "Coral," "Sea Foam," "American Denim," "Pretty In Pink," and "Charcoal." The company is currently selling packs of 10 to determine which colors get the most traction, with plans to offer larger bundles of the most popular colors.

Research backed by the Center for Disease Control now shows that wearing masks can drastically reduce the spread of COVID-19 across the country, with surgical masks being more effective than cloth. However, getting the majority of people in the U.S. to wear them has proved challenging, which is one area American manufacturing can help correct.

"The advantage of American manufacturing is being able to understand the market and make changes to your products quickly. Since most masks are made in China and sold to resellers, it probably doesn't make financial sense to offer more than one ugly color," Armbrust explained. "If adding new color options gets more people wearing masks, then it becomes more than just a cosmetic change, not to mention a true testament to the need for strategic manufacturing to return to the U.S."

About Armbrust American
Armbrust American's mission is to bring strategic manufacturing back to the U.S. Founded in 2020 by Y-Combinator alumni Lloyd Armbrust, the company currently operates a factory out of Austin, Texas utilizing proprietary mix of materials and manufacturing innovation to provide the highest quality PPE at a competitive cost. Lloyd was previously the founder and CEO of OwnLocal, a company that automates production for 3,500 newspapers worldwide.

Armbrust American Debuts New Surgical Mask Colors (2-min)

Introduction Video: About Armbrust American (2-min)

For more info, visit: https://www.armbrustusa.com/

Media Contact:
Tom Cheredar
[email protected] 
Ph: (512) 831-4409

SOURCE Armbrust American


These press releases may also interest you

at 09:05
...

at 09:00
Coveo , a leading provider of enterprise AI Search, Recommendations and Generative Experience platforms that enable individualized, connected, and trusted digital experiences at scale with unified relevance, today announced two new GenAI business...

at 08:49
Cove Capital Investments reviews and analyzes nearly every type of asset class available for Delaware Statutory Trust investors.  This list of potential DST property asset classes includes government leased buildings, self-storage facilities,...

at 08:40
The "United States Self-Monitoring Blood Glucose Devices Market Growth, Share, Size, Trends, Analysis and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering. The U.S. Self-Monitoring Blood Glucose Devices market size...

at 08:35
Arch Insurance North America (Arch), a provider of specialized insurance and risk management solutions, today unveiled its latest products available through the Arch APEX? digital platform. Participant Accident coverage is now available for child...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...



News published on and distributed by: